ArticleBMJ open2026
Racial and Socioeconomic Determinants of Major Adverse Liver Outcomes in Patients with Coexisting Inflammatory Bowel Disease and Chronic Liver Disease: Insights from the National Inpatient Sample.
Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInflammatory bowel disease (IBD) is associated with worse major adverse liver outcomes (MALO) in patients with chronic liver disease (CLD). Although the interplay between these conditions is recognised, the contribution of external factors such as race and socioeconomic status (SES) remains unclear. We aimed to assess the association of race and socioeconomic factors with MALO in patients with IBD and CLD.
methodsThis retrospective cohort study analysed hospitalised adults with IBD and CLD using the National Inpatient Sample database (2015-2021). Demographic variables included age, sex and race. SES included household income. Clinical variables included length of hospital stay, in-hospital mortality and comorbidities. A multivariate logistic regression analysis was performed to assess the independent associations between MALO and patient demographics, comorbidities and social determinants of health.
resultsAmong 97 628 hospitalised adult patients with IBD, 4.11% (4011/97 628) had secondary CLD. The majority of patients with IBD-CLD were white (74.94% or 2928/3907), and over half (53.83% or 2118/3934) resided in lower-income households with incomes below US$35 000. Racial disparities were evident, with significant differences in comorbidities such as sepsis, cholangitis and hepatocellular carcinoma. Among white patients, the prevalence of depression and anxiety was 20.18% (591/2928) and 24.21% (709/2928), respectively, which was higher compared with other racial groups. In adjusted analyses, African American race (OR 1.42, p=0.003) and lowest SES (OR 1.19, p=0.04) were independently associated with increased odds of MALO.
conclusionsAfrican American race and lower SES are independently associated with higher odds of MALO in patients with IBD-CLD. These findings highlight disparities that warrant further investigation and suggest that targeted interventions may help improve liver-related outcomes. Interventions reducing health inequities are desperately needed to mitigate disparities in this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.